Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 24, 2010
- Accepted December 14, 2010
- Published online February 2, 2011.
Article Versions
- Older version (January 17, 2011 - 13:44).
- You are viewing the most recent version of this article.
Author Information
- Ivett Jelinek*,
- Joshua N. Leonard*,1,
- Graeme E. Price†,
- Kevin N. Brown*,
- Anna Meyer-Manlapat*,2,
- Paul K. Goldsmith‡,
- Yan Wang*,
- David Venzon§,
- Suzanne L. Epstein† and
- David M. Segal*
- *Experimental Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;
- †Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852;
- ‡Antibody and Protein Purification Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; and
- §Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
- Address correspondence and reprint requests to Dr. David M. Segal, Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 4B36, 10 Center Drive, Bethesda, MD 20892-1360. E-mail address: dave_segal{at}nih.gov
Article usage
In this issue
TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection
